Home › Funds › SILVERARC CAPITAL MANAGEMENT, LLC › GLUE
SILVERARC CAPITAL MANAGEMENT, LLC position in GLUE
MONTE ROSA THERAPEUTICS INC · Health Care
SILVERARC CAPITAL MANAGEMENT, LLC reported holding 525,000 shares of GLUE (MONTE ROSA THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$6.3M, representing 0.80% of its reported portfolio and ranking #34 among its reported holdings. SILVERARC CAPITAL MANAGEMENT, LLC has disclosed GLUE holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR
How SILVERARC CAPITAL MANAGEMENT, LLC's GLUE position evolved
SILVERARC CAPITAL MANAGEMENT, LLC first disclosed a stake in GLUE in Q3 2025 at 694,942 shares (US$5.1M). The position peaked in Q1 2026 at 2,002,040 shares, worth US$32.9M. Across 5 filings, SILVERARC CAPITAL MANAGEMENT, LLC increased the stake 3 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 525,000 shares valued at US$6.3M — an increase of 225,000 shares quarter over quarter.. Notable position changes include a 95% increase in Q1 2026 (shares rose 47% over the following quarter), a 85% trim in Q2 2026 (shares fell 51% over the following quarter), a 75% increase in Q3 2026 (shares fell 21% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 694.94K | $5.15M | New |
| Q4 2025 | 1.03M | $16.14M | Add |
| Q1 2026 | 2.00M | $32.93M | Add |
| Q2 2026 | 300.00K | $7.26M | Reduce |
| Q3 2026 | 525.00K | $6.26M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About GLUE and 13F data
GLUE (MONTE ROSA THERAPEUTICS INC) is a Health Care company. 65 other funds we track also report a position in GLUE — the largest reported positions include NEA Management Company, LLC (US$186.2M), TCG Crossover Management, LLC (US$111.9M), Vestal Point Capital, LP (US$111.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding GLUE
- NEA Management Company, LLC 7.69M sh · $186.15M · Q2 2026
- TCG Crossover Management, LLC 4.62M sh · $111.86M · Q2 2026
- Vestal Point Capital, LP 4.60M sh · $111.32M · Q2 2026
- BVF INC/IL 4.46M sh · $107.95M · Q2 2026
- BAKER BROS. ADVISORS LP 4.35M sh · $105.17M · Q2 2026
- MONTANOVA CAPITAL, LLC 3.55M sh · $85.90M · Q2 2026
- Versant Venture Management, LLC 3.18M sh · $76.97M · Q2 2026
- BRAIDWELL LP 2.45M sh · $59.33M · Q2 2026
- Bellevue Group AG 1.19M sh · $28.80M · Q2 2026
- MPM BioImpact LLC 1.16M sh · $28.10M · Q2 2026
- Frazier Life Sciences Management, L.P. 1.00M sh · $24.20M · Q2 2026
- Aisling Capital Management LP 1.56M sh · $18.56M · Q3 2026
More on SILVERARC CAPITAL MANAGEMENT, LLC
FAQ
How long has SILVERARC CAPITAL MANAGEMENT, LLC held GLUE?
SILVERARC CAPITAL MANAGEMENT, LLC has disclosed GLUE holdings in 5 of the last 5 reported quarters, going back to Q3 2025.
What is SILVERARC CAPITAL MANAGEMENT, LLC's current position in GLUE?
As of Q3 2026, SILVERARC CAPITAL MANAGEMENT, LLC holds 525.00K shares of GLUE (MONTE ROSA THERAPEUTICS INC), valued at $6.26M, representing 0.80% of its reported portfolio and ranking #34.
Has SILVERARC CAPITAL MANAGEMENT, LLC been buying or selling GLUE?
In the latest 13F filing (Q3 2026), SILVERARC CAPITAL MANAGEMENT, LLC increased its position in GLUE. The position peaked in Q1 2026 at 2.00M shares.
Which other funds hold GLUE?
Other major institutional holders of GLUE include NEA Management Company, LLC, TCG Crossover Management, LLC, Vestal Point Capital, LP, among 65 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.